HRP20211492T1 - Liraglutid, namijenjen upotrebi kod kardiovaskularnih stanja - Google Patents
Liraglutid, namijenjen upotrebi kod kardiovaskularnih stanja Download PDFInfo
- Publication number
- HRP20211492T1 HRP20211492T1 HRP20211492TT HRP20211492T HRP20211492T1 HR P20211492 T1 HRP20211492 T1 HR P20211492T1 HR P20211492T T HRP20211492T T HR P20211492TT HR P20211492 T HRP20211492 T HR P20211492T HR P20211492 T1 HRP20211492 T1 HR P20211492T1
- Authority
- HR
- Croatia
- Prior art keywords
- liraglutide
- intended
- accordance
- approximately
- cardiovascular
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16158739 | 2016-03-04 | ||
| EP16173917 | 2016-06-10 | ||
| EP16001329 | 2016-06-13 | ||
| US15/401,651 US9968659B2 (en) | 2016-03-04 | 2017-01-09 | Liraglutide in cardiovascular conditions |
| EP17710160.7A EP3423082B1 (en) | 2016-03-04 | 2017-03-03 | Liraglutide in cardiovascular conditions |
| PCT/EP2017/054990 WO2017149112A1 (en) | 2016-03-04 | 2017-03-03 | Liraglutide in cardiovascular conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211492T1 true HRP20211492T1 (hr) | 2021-12-24 |
Family
ID=59723004
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211492TT HRP20211492T1 (hr) | 2016-03-04 | 2017-03-03 | Liraglutid, namijenjen upotrebi kod kardiovaskularnih stanja |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US9968659B2 (enExample) |
| EP (1) | EP3423082B1 (enExample) |
| JP (1) | JP6940512B2 (enExample) |
| KR (1) | KR102417455B1 (enExample) |
| CN (2) | CN116327897A (enExample) |
| AU (2) | AU2017225841A1 (enExample) |
| BR (1) | BR112018067344A2 (enExample) |
| CA (1) | CA3013532C (enExample) |
| CL (1) | CL2018002515A1 (enExample) |
| DK (1) | DK3423082T5 (enExample) |
| ES (1) | ES2893755T3 (enExample) |
| HR (1) | HRP20211492T1 (enExample) |
| HU (1) | HUE055844T2 (enExample) |
| IL (1) | IL261169B (enExample) |
| MA (1) | MA43704A (enExample) |
| MX (1) | MX394179B (enExample) |
| MY (1) | MY195657A (enExample) |
| PH (1) | PH12018501844B1 (enExample) |
| PL (1) | PL3423082T3 (enExample) |
| RS (1) | RS62501B1 (enExample) |
| RU (1) | RU2745604C2 (enExample) |
| SI (1) | SI3423082T1 (enExample) |
| WO (1) | WO2017149112A1 (enExample) |
| ZA (1) | ZA201805538B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9968659B2 (en) | 2016-03-04 | 2018-05-15 | Novo Nordisk A/S | Liraglutide in cardiovascular conditions |
| US12569543B2 (en) | 2016-04-28 | 2026-03-10 | Novo Nordisk A/S | Semaglutide in cardiovascular conditions |
| CA3056663C (en) | 2019-04-05 | 2022-10-18 | Jeffrey S. RIESMEYER | Use of dulaglutide in reducing risk of cardiovascular events in patients with type 2 diabetes mellitus |
| CN118987224A (zh) * | 2020-12-16 | 2024-11-22 | 香港中文大学 | 一种治疗受试者的衰老相关脑功能障碍的组合物及其应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5808203A (en) | 1997-05-12 | 1998-09-15 | Medrad, Inc. | Fluid pressure measurement devices |
| JP2005535569A (ja) * | 2002-04-04 | 2005-11-24 | ノボ・ノルデイスク・エー／エス | Ｇｌｐ−１アゴニスト及び心臓血管合併症 |
| PT1687019T (pt) * | 2003-11-20 | 2018-02-26 | Novo Nordisk As | Formulações de péptidos que contêm polietileno glicol que são ótimas para produção e para utilização em dispositivos de injeção |
| CN112618700A (zh) * | 2004-11-12 | 2021-04-09 | 诺和诺德公司 | 促胰岛素肽的稳定制剂 |
| ES2672770T3 (es) * | 2007-09-05 | 2018-06-18 | Novo Nordisk A/S | Derivados del péptido-1 similar al glucagón y su uso farmacéutico |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
| TWI466672B (zh) | 2009-01-29 | 2015-01-01 | Boehringer Ingelheim Int | 小兒科病人糖尿病之治療 |
| SG174504A1 (en) | 2009-03-27 | 2011-10-28 | Bristol Myers Squibb Co | Methods for preventing major adverse cardiovascular events with dpp-iv inhibitors |
| JP2013525491A (ja) | 2010-05-04 | 2013-06-20 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 心血管障害を治療または予防し心血管保護を提供する方法 |
| NZ603319A (en) | 2010-06-24 | 2015-04-24 | Boehringer Ingelheim Int | Diabetes therapy |
| AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
| US20130172244A1 (en) * | 2011-12-29 | 2013-07-04 | Thomas Klein | Subcutaneous therapeutic use of dpp-4 inhibitor |
| US20130303554A1 (en) | 2012-05-14 | 2013-11-14 | Boehringer Ingelheim International Gmbh | Use of a dpp-4 inhibitor in sirs and/or sepsis |
| EP3685839A1 (en) | 2012-05-14 | 2020-07-29 | Boehringer Ingelheim International GmbH | Linagliptin for use in the treatment of albuminuria and kidney related diseases |
| JP6374862B2 (ja) | 2012-05-24 | 2018-08-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 自己免疫性糖尿病、特に、ｌａｄａの治療に使用するためのｄｐｐ−４阻害剤としてのキサンチン誘導体 |
| CN103893744B (zh) * | 2012-12-24 | 2017-12-19 | 杭州九源基因工程有限公司 | 一种治疗糖尿病的药物制剂及其制备方法 |
| KR20210099201A (ko) | 2013-03-15 | 2021-08-11 | 베링거 인겔하임 인터내셔날 게엠베하 | 심장보호 및 신장보호 항당뇨병 치료요법에서의 리나글립틴의 사용 |
| WO2014198906A1 (en) | 2013-06-14 | 2014-12-18 | Boehringer Ingelheim International Gmbh | Dpp-4 inhibitors for treating diabetes and its complications |
| US8969371B1 (en) | 2013-12-06 | 2015-03-03 | Orexigen Therapeutics, Inc. | Compositions and methods for weight loss in at risk patient populations |
| ES2950384T3 (es) | 2014-02-28 | 2023-10-09 | Boehringer Ingelheim Int | Uso médico de un inhibidor de DPP-4 |
| WO2016019587A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | [7, 6]-fused bicyclic antidiabetic compounds |
| US9968659B2 (en) | 2016-03-04 | 2018-05-15 | Novo Nordisk A/S | Liraglutide in cardiovascular conditions |
-
2017
- 2017-01-09 US US15/401,651 patent/US9968659B2/en active Active
- 2017-03-03 MY MYPI2018702782A patent/MY195657A/en unknown
- 2017-03-03 SI SI201730917T patent/SI3423082T1/sl unknown
- 2017-03-03 HU HUE17710160A patent/HUE055844T2/hu unknown
- 2017-03-03 KR KR1020187026962A patent/KR102417455B1/ko active Active
- 2017-03-03 EP EP17710160.7A patent/EP3423082B1/en not_active Revoked
- 2017-03-03 DK DK17710160.7T patent/DK3423082T5/da active
- 2017-03-03 BR BR112018067344A patent/BR112018067344A2/pt unknown
- 2017-03-03 MA MA043704A patent/MA43704A/fr unknown
- 2017-03-03 CA CA3013532A patent/CA3013532C/en not_active Expired - Fee Related
- 2017-03-03 MX MX2018010097A patent/MX394179B/es unknown
- 2017-03-03 AU AU2017225841A patent/AU2017225841A1/en not_active Abandoned
- 2017-03-03 JP JP2018546477A patent/JP6940512B2/ja active Active
- 2017-03-03 PH PH1/2018/501844A patent/PH12018501844B1/en unknown
- 2017-03-03 CN CN202310320736.6A patent/CN116327897A/zh not_active Withdrawn
- 2017-03-03 RU RU2018134061A patent/RU2745604C2/ru active
- 2017-03-03 CN CN201780015266.5A patent/CN108778317A/zh active Pending
- 2017-03-03 ES ES17710160T patent/ES2893755T3/es active Active
- 2017-03-03 HR HRP20211492TT patent/HRP20211492T1/hr unknown
- 2017-03-03 WO PCT/EP2017/054990 patent/WO2017149112A1/en not_active Ceased
- 2017-03-03 RS RS20211250A patent/RS62501B1/sr unknown
- 2017-03-03 PL PL17710160T patent/PL3423082T3/pl unknown
-
2018
- 2018-04-18 US US15/956,445 patent/US20180236038A1/en not_active Abandoned
- 2018-08-15 IL IL26116918A patent/IL261169B/en unknown
- 2018-08-20 ZA ZA2018/05538A patent/ZA201805538B/en unknown
- 2018-09-03 CL CL2018002515A patent/CL2018002515A1/es unknown
-
2024
- 2024-03-26 AU AU2024201937A patent/AU2024201937A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20240485T1 (hr) | Pripravci glp-1 i njihova upotreba | |
| ES2543383T3 (es) | Tratamiento de tumores de mama con un derivado de rapamicina en combinación con exemestano | |
| ES2508290T3 (es) | Composición farmacéutica para la administracón de compuestos de inhibición del receptor de tirosina cinasa (RTKI) al ojo | |
| JP2015038135A5 (enExample) | ||
| AR052198A1 (es) | Formulaciones anticuerpo anti a beta | |
| FI3506886T3 (fi) | Erittäin väkevöityjä alhaisen viskositeetin masp-2:ta estäviä vasta-aineformulaatioita, tarvikesarjoja ja menetelmiä | |
| ME03797B (me) | Stabilne formulacije koje sadrže anti-pcsk9 antitela | |
| RU2018119295A (ru) | Фармацевтические составы для местного применения для лечения связанных с воспалением состояний | |
| AR094374A1 (es) | Composiciones y métodos para el tratamiento de trastornos metabólicos | |
| HRP20250628T1 (hr) | Mješavine antitijela i postupci njihove upotrebe | |
| BRPI0213425B8 (pt) | composições injetáveis para a liberação controlada de composto farmacologicamente ativo, usos do referido composto e método para suas preparações | |
| JP2010248207A5 (enExample) | ||
| PE20120204A1 (es) | Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas | |
| PE20040121A1 (es) | Formulaciones farmaceuticas de liberacion controlada del 5,8,14-triazatetraciclo [10.3.1.02,11.04.9]-hexadeca-2-(11),3,5,7,9-pentaeno | |
| HRP20250278T1 (hr) | Puferovane formulacije eksendina (9-39) | |
| RU2016119746A (ru) | Стабильный состав инсулина глулизин | |
| CO2019008053A2 (es) | Agente terapéutico para enfermedades del hígado | |
| AR077436A1 (es) | Composiciones farmaceuticas para el tratamiento del cancer y otras enfermedades o trastornos que contienen el 4-{[9-cloro-7-(2-fluoro-6-metoxifenil)-5h-pirimido-[5,4-d][2]benzacepin-2-il]amino}-2-metoxibenzoico, o una de sus sales farmaceuticamente aceptables. | |
| HRP20221150T1 (hr) | Semaglutid u kardiovaskularnim stanjima | |
| HRP20241052T1 (hr) | Semaglutid, namijenjen liječenju alzheimerove demencije | |
| CO6260085A2 (es) | Composicion farmaceutica que contiene una combinacion sinergica de venotonicos y vasoprotectores | |
| IL309340A (en) | Dosing regimen for missing doses of paliperidone long-acting injectable esters | |
| HRP20231587T1 (hr) | Kronično noćno doziranje lasmiditana radi sprječavanja migrene | |
| JP2019507174A5 (enExample) | ||
| JP2020510043A5 (enExample) |